MDGL
Price
$298.87
Change
-$1.28 (-0.43%)
Updated
Jul 3 closing price
Capitalization
6.64B
32 days until earnings call
SGMO
Price
$0.53
Change
-$0.01 (-1.85%)
Updated
Jul 3 closing price
Capitalization
129.3M
38 days until earnings call
Interact to see
Advertisement

MDGL vs SGMO

Header iconMDGL vs SGMO Comparison
Open Charts MDGL vs SGMOBanner chart's image
Madrigal Pharmaceuticals
Price$298.87
Change-$1.28 (-0.43%)
Volume$108.67K
Capitalization6.64B
Sangamo Therapeutics
Price$0.53
Change-$0.01 (-1.85%)
Volume$1.98M
Capitalization129.3M
MDGL vs SGMO Comparison Chart in %
Loading...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MDGL vs. SGMO commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDGL is a StrongBuy and SGMO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (MDGL: $298.87 vs. SGMO: $0.53)
Brand notoriety: MDGL and SGMO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MDGL: 34% vs. SGMO: 39%
Market capitalization -- MDGL: $6.64B vs. SGMO: $129.3M
MDGL [@Biotechnology] is valued at $6.64B. SGMO’s [@Biotechnology] market capitalization is $129.3M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MDGL’s FA Score shows that 0 FA rating(s) are green whileSGMO’s FA Score has 0 green FA rating(s).

  • MDGL’s FA Score: 0 green, 5 red.
  • SGMO’s FA Score: 0 green, 5 red.
According to our system of comparison, MDGL is a better buy in the long-term than SGMO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MDGL’s TA Score shows that 5 TA indicator(s) are bullish while SGMO’s TA Score has 3 bullish TA indicator(s).

  • MDGL’s TA Score: 5 bullish, 4 bearish.
  • SGMO’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than SGMO.

Price Growth

MDGL (@Biotechnology) experienced а -0.21% price change this week, while SGMO (@Biotechnology) price change was -5.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

MDGL is expected to report earnings on Aug 06, 2025.

SGMO is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($6.64B) has a higher market cap than SGMO($129M). MDGL YTD gains are higher at: -3.144 vs. SGMO (-48.343). SGMO has higher annual earnings (EBITDA): -72.14M vs. MDGL (-376.15M). MDGL has more cash in the bank: 843M vs. SGMO (25.2M). SGMO has less debt than MDGL: SGMO (24.9M) vs MDGL (120M). MDGL has higher revenues than SGMO: MDGL (317M) vs SGMO (63.8M).
MDGLSGMOMDGL / SGMO
Capitalization6.64B129M5,144%
EBITDA-376.15M-72.14M521%
Gain YTD-3.144-48.3437%
P/E RatioN/AN/A-
Revenue317M63.8M497%
Total Cash843M25.2M3,345%
Total Debt120M24.9M482%
FUNDAMENTALS RATINGS
MDGL vs SGMO: Fundamental Ratings
MDGL
SGMO
OUTLOOK RATING
1..100
1472
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
79
Overvalued
PROFIT vs RISK RATING
1..100
42100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5762
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a48

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (64) in the Pharmaceuticals Other industry is in the same range as SGMO (79) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SGMO’s over the last 12 months.

MDGL's Profit vs Risk Rating (42) in the Pharmaceuticals Other industry is somewhat better than the same rating for SGMO (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than SGMO’s over the last 12 months.

MDGL's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as SGMO (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SGMO’s over the last 12 months.

MDGL's Price Growth Rating (57) in the Pharmaceuticals Other industry is in the same range as SGMO (62) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SGMO’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as SGMO (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to SGMO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MDGLSGMO
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
89%
Momentum
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 11 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
81%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SGMO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GEBHY3.60N/A
N/A
Genting Berhad
ADERY55.00N/A
N/A
Aida Engineering Co., Ltd.
KEGX0.86N/A
N/A
Key Energy Services Inc. Del
NEXOF19.99N/A
N/A
Nexon Co Ltd.
MMTIF0.05-0.01
-10.51%
Micromem Technologies, Inc.

SGMO and

Correlation & Price change

A.I.dvisor indicates that over the last year, SGMO has been loosely correlated with AXON. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SGMO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SGMO
1D Price
Change %
SGMO100%
-1.51%
AXON - SGMO
51%
Loosely correlated
+2.70%
ARRY - SGMO
48%
Loosely correlated
+11.93%
BCRX - SGMO
46%
Loosely correlated
-0.89%
RPRX - SGMO
45%
Loosely correlated
+0.50%
AGEN - SGMO
43%
Loosely correlated
+10.16%
More